

Sheppard Mullin Advised Instem in Acquisition of Xybion

08.01.2025

The firm represented ArchiMed-backed Instem in its acquisition of Xybion Digital from Banerjee Group. Instem is a leading supplier of SaaS platforms across discovery, study management, regulatory submission and clinical trial analytics. Xybion is best known for its Pristima™ preclinical study management platform. Like Instem, Xybion has primarily focused on serving life sciences customers, particularly CROs, Pharma and Biotechnology firms.

The combination allows Instem to meet the needs of all life sciences users in preclinical study management. Financial terms were not disclosed.

The Sheppard Mullin deal team that represented Instem was led by partners Valerie Demont and Matt McCalip and associates Teresita Acedo and Edouard Goguillon. Invaluable assistance was provided by partners Niya Tang, Dmitry Chelnitsky, Daniel Yannuzzi, Sean Kirby, Townsend Bourne, Reid Whitten, Jared Nagley and Carolyn Metnick, special counsels Malika Levarlet and Sally Elshihabi, and associates Julien Blanquart, Theo Mayer, Michael Weisshar, Iman Naieem, Cortney Inman, Michael Sutton, Daniel Alvarado and Sidrah Amin.

[Read the press release here.](#)

Attorneys

Teresita Acedo

Sidrah Amin

Julien Blanquart

Townsend L. Bourne

Dmitriy Chelnitsky

Valérie Demont

Sally Elshihabi

Edouard Goguillon

Cortney Inman

Sean J. Kirby

Malika Levarlet

Theo Mayer

Matthew A. McCalip

Carolyn V. Metnick

Jared P. Nagley

Iman Naieem

Michael D. Sutton

Niya Tang

Michael H. Weissnar

Reid Whitten

Daniel N. Yannuzzi

Practice Areas

Corporate

International Reach

Mergers and Acquisitions

Private Equity